4D Molecular Therapeutics, Inc. SEC filings FDMT
4D Molecular Therapeutics, Inc. has 439 filings in SEC EDGAR's recent list, going back to Aug 13, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Jul 20, 2026 | Jul 18, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jun 29, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 30, 2026 | Mar 25, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 18, 2026 | Mar 18, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Jan 26, 2026 | Jan 22, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Jan 7, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Other events
|
Dec 10, 2025 | Dec 10, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 17, 2025 | Nov 17, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| 8-K |
Current report
Other events
|
Nov 7, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement
|
Oct 31, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Oct 2, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Jul 2, 2025 | Jun 27, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 20, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 28, 2025 | Feb 28, 2025 |
| 8-K |
Current report
Other events
|
Feb 10, 2025 | Feb 8, 2025 |
| 8-K |
Current report
Results of operations, Other events
|
Jan 10, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Unregistered share sale
|
Dec 11, 2024 | Dec 6, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Other events
|
Sep 18, 2024 | Sep 18, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 23, 2024 | Jul 23, 2024 |
| 8-K |
Current report
Other events
|
Jul 17, 2024 | Jul 17, 2024 |
| 8-K |
Current report
Material agreement
|
Jun 7, 2024 | Jun 7, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 24, 2024 | May 21, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 29, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Other events
|
Feb 9, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 4, 2024 | Jan 1, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 22, 2023 | Nov 16, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 13, 2023 | Sep 11, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 9, 2023 | Aug 9, 2023 |
| 8-K |
Current report
Material agreement
|
Jul 11, 2023 | Jul 5, 2023 |
| 8-K |
Current report
Shareholder vote results
|
May 25, 2023 | May 23, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 10, 2023 |
| 8-K |
Current report
Other events
|
May 9, 2023 | May 4, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 15, 2023 | Mar 15, 2023 |
| 8-K |
Current report
Other events
|
Feb 3, 2023 | Feb 2, 2023 |
| 8-K |
Current report
Other events
|
Jan 26, 2023 | Jan 9, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Officer or director change
|
Sep 27, 2022 | Sep 23, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jun 21, 2022 | Jun 14, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 27, 2022 | May 23, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2022 | Mar 28, 2022 |
| 8-K |
Current report
Officer or director change
|
Feb 22, 2022 | Feb 17, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 11, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Other events
|
Oct 26, 2021 | Oct 25, 2021 |
| 8-K |
Current report
Other events
|
Oct 13, 2021 | Oct 10, 2021 |
| 8-K |
Current report
Officer or director change
|
Sep 24, 2021 | Sep 22, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 8-K |
Current report
Agreement ended, Other events
|
Jun 25, 2021 | Jun 18, 2021 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2021 | May 17, 2021 |
| 8-K |
Current report
Results of operations
|
May 13, 2021 | May 13, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 25, 2021 | Mar 25, 2021 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Dec 15, 2020 | Dec 15, 2020 |
Showing 66 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FDMT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1650648
- Former names
- 4D Molecular Therapeutics Inc. (until May 12, 2022); 4D Molecular Therapeutics Inc (until Sep 30, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.